Cargando…

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug’s overall effectiveness. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prior-Español, A., Sánchez-Piedra, C., Campos, J., Manero, F. J., Pérez-García, C., Bohórquez, C., Busquets-Pérez, N., Blanco-Madrigal, J. M., Díaz-Torne, C., Sánchez-Alonso, F., Mateo, L., Holgado-Pérez, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159943/ https://www.ncbi.nlm.nih.gov/pubmed/34045525 http://dx.doi.org/10.1038/s41598-021-90442-w

Ejemplares similares

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
por: Sánchez-Piedra, Carlos, et al.
Publicado: (2021)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
por: Vela, Paloma, et al.
Publicado: (2020)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
por: De La Fuente, Fanny, et al.
Publicado: (2022)

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
por: Jeong, Seogsong, et al.
Publicado: (2022)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
por: Tobudic, Selma, et al.
Publicado: (2023)

Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
por: Lu, Yuqiong, et al.
Publicado: (2022)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS
por: Mirzaei, Alireza, et al.
Publicado: (2021)

bDMARDs retention rate in the biosimilar era: A real-life monocentric study
por: Becciolini, Andrea, et al.
Publicado: (2021)

Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis
por: Sakellariou, Garifallia, et al.
Publicado: (2021)

Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis
por: Lee, Seulkee, et al.
Publicado: (2021)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
por: Gerardi, Maria Chiara, et al.
Publicado: (2022)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis
por: Suto, Takahito, et al.
Publicado: (2023)

4β‐Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State
por: Wollmann, BM, et al.
Publicado: (2016)

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
por: Bethencourt Baute, Juan José, et al.
Publicado: (2018)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
por: Reyes, Juan M., et al.
Publicado: (2023)

Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate
por: Batticciotto, Alberto, et al.
Publicado: (2016)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs
por: Lurati, Alfredomaria, et al.
Publicado: (2021)

Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
por: Ravasio, Roberto
Publicado: (2017)

MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2021)

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
por: Geurts-Voerman, Gerlienke E., et al.
Publicado: (2020)

Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
por: Rintelen, Bernhard, et al.
Publicado: (2016)

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
por: Barbulescu, Andrei, et al.
Publicado: (2022)

Erratum to: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
por: Rintelen, Bernhard, et al.
Publicado: (2016)

Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid Arthritis
por: Miwa, Yusuke, et al.
Publicado: (2017)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
por: Gottlieb, Alice B, et al.
Publicado: (2018)

Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort
por: Sapart, Emilie, et al.
Publicado: (2023)

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
por: Vinson, D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d8hqk0fojhk7ipmknp8896nbik